

ForPatients

by Roche

Pancreatic Cancer Pancreatic Adenocarcinoma

## A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

**Trial Status**

Active, not recruiting

**Trial Runs In**

5 Countries

**Trial Identifier**

NCT03193190 2016-004126-42  
WO39608

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. In each cohort, eligible patients will be assigned to one of several treatment arms.

**Hoffmann-La Roche**

Sponsor

**Phase 1/Phase 2**

Phase

**NCT03193190 2016-004126-42 WO39608**

Trial Identifiers

### *Eligibility Criteria:*

**Gender**

All

**Age**

>= 18 Years

**Healthy Volunteers**

No